SFA-009

About SFA Therapeutics

SFA Therapeutics is pioneering a novel, oral approach to treating autoimmune diseases by restoring immune tolerance through the gut-immune axis, aiming to avoid broad immunosuppression. Its lead asset, SFA-002 for plaque psoriasis, has generated promising Phase 1b safety and efficacy data and is advancing toward a Phase 2 trial. The company's platform, which deuterationally modifies endogenous SCFAs, also has preclinical programs in oncology and other autoimmune indications, positioning it to address large, underserved markets with a potentially safer, more convenient therapeutic modality.

Therapeutic Areas